Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 178 entries
View as:

A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT02625259 Org: User:
Start: 01/08/16 End: 07/22/16 Due: 07/22/17

TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI)

Phase: N/A Priority: Normal
NCT ID: NCT03477903 Org: User:
Start: 08/25/18 End: 08/29/18 Due: 08/29/19

A Study of MLN0264 in Patients With Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02202785 Org: User:
Start: 07/02/14 End: 01/15/16 Due: 01/15/17

A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT03849690 Org: User:
Start: 02/27/19 End: 04/15/19 Due: 04/15/20

Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00935844 Org: User:
Start: 10/31/09 End: 11/30/11 Due: 11/30/12

Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00715208 Org: User:
Start: 09/30/08 End: 03/31/11 Due: 03/31/12

A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease

Phase: N/A Priority: Normal
NCT ID: NCT03701555 Org: User:
Start: 06/19/18 End: 07/02/21 Due: 07/02/22

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02327169 Org: User:
Start: 01/14/15 End: 07/02/18 Due: 07/02/19

Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

Phase: N/A Priority: Normal
NCT ID: NCT02038647 Org: User:
Start: 05/12/14 End: 07/10/17 Due: 07/10/18

Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT00931918 Org: User:
Start: 10/31/09 End: 08/31/15 Due: 08/31/16

A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00535522 Org: User:
Start: 08/31/07 End: 06/30/11 Due: 06/30/12

PROTECT-TIMI 30 Trial

Phase: N/A Priority: Normal
NCT ID: NCT00250471 Org: User:
Start: 05/31/03 End: 09/30/04 Due: 09/30/05

A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00297921 Org: User:
Start: - End: - Due: -

Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00312845 Org: User:
Start: 03/31/06 End: 07/31/10 Due: 07/31/11

Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT01177228 Org: User:
Start: 05/31/07 End: 09/30/08 Due: 09/30/09

Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02046070 Org: User:
Start: 03/05/14 End: 06/29/18 Due: 06/29/19

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Phase: N/A Priority: Normal
NCT ID: NCT03439280 Org: User:
Start: 04/20/18 End: 01/28/22 Due: 01/28/23

A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03482453 Org: User:
Start: 03/28/18 End: 01/18/19 Due: 01/18/20

Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT00619489 Org: User:
Start: 12/31/07 End: 03/31/10 Due: 03/31/11

Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00831896 Org: User:
Start: 03/31/09 End: 05/31/11 Due: 05/31/12

Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients

Phase: N/A Priority: Normal
NCT ID: NCT00507442 Org: User:
Start: 08/31/07 End: 11/30/10 Due: 11/30/11

Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB

Phase: N/A Priority: Normal
NCT ID: NCT01953783 Org: User:
Start: 03/19/14 End: 02/09/16 Due: 02/09/17

MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00274248 Org: User:
Start: 03/31/05 End: - Due: -

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)

Phase: N/A Priority: Normal
NCT ID: NCT03724916 Org: User:
Start: 11/26/18 End: 11/04/21 Due: 11/04/22

Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C

Phase: N/A Priority: Normal
NCT ID: NCT01577758 Org: User:
Start: 06/30/12 End: 02/28/14 Due: 02/28/15